Journal decision profile

Drugs & Aging

Medicine

Drugs & Aging's 2026 Journal Metrics Score is 4.3, ranking Q1 in Geriatrics and Gerontology and 3 other subfields. Two-year citation average from OpenAlex data, updated August 2026.

Adis, Springer HealthcareNew ZealandpISSN 1170-229XeISSN 1179-1969
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
4.3

Journal Metrics Score 2026 · 2021–2024 window citedness 4.75.

Submission-to-acceptance
i
Submission-to-acceptanceCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED

Not available — there are not enough recent PubMed records with both received and accepted dates.

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$4,990

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

Free preview · no sign-in

Does your manuscript fit Drugs & Aging?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
4.32026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#160 / 2,029LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
21.6%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
1.39MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
—NOT AVAILABLE
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
85 / yr2021–2024 AVG
Field-normalized top 10% share21.6%

73 of 338 works · same type, year & subfield

Field-normalized top 1% share2.4%

8 works · same type, year & subfield

Median FWCI1.39×

Above field-year expectation

Source output rank#160

of 2,029 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 1.39, so its typical recent paper runs about 39% above its field benchmark.

What does Top 10% Share mean?

21.6% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

912016
812017
1132018
1092019
912020
862021
792022
942023
792024
1042025

Recent work-type mix

338 OpenAlex works · 2021–2024

Article86.1%
Review9.2%
Erratum3%
Paratext1.2%
Letter0.6%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works

Select a MeSH signal to see how much Drugs & Aging publishes on it, from PubMed counts for the last five complete years.

Leading OpenAlex topics

2021–2024 works
Pharmaceutical Practices and Patient Outcomes102
Atrial Fibrillation Management and Outcomes11
Pain Management and Opioid Use11
Heart Failure Treatment and Management10
Dementia and Cognitive Impairment Research9
Urinary Bladder and Prostate Research9
Opioid Use Disorder Treatment8
Cannabis and Cannabinoid Research6
Blood Pressure and Hypertension Studies5
Epilepsy research and treatment5
Methodology: OpenAlex snapshot 2026-10-16. FWCI, percentile badges, topics, and type mix use 338 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Geriatrics and GerontologyQ1
Family PracticeQ1
Psychiatry and Mental healthQ1
Economics and EconometricsQ1

Is Drugs & Aging a good journal?

Yes. A Q1 journal by citation data

Yes. By citation data, Drugs & Aging is a strong journal: it is Q1 in Geriatrics and Gerontology and 3 other subfields and ranks #722 of 6,272 Medicine journals by Journal Metrics Score (top 12%). Drugs & Aging's 2026 Journal Metrics Score is 4.3. OpenAlex lists an indicative article processing charge of $4,990 USD. OpenAlex classifies its papers in subfields including Geriatrics and Gerontology, Family Practice, and Psychiatry and Mental health, so check that your topic fits its scope.

Best quartile
Q1
Geriatrics and Gerontology
Rank in Medicine
#722 of 6,272
Top 12%
2026 Journal Metrics Score
4.3
Acceptance rate
Not published
By the journal or publisher
Indicative APC
$4,990
OpenAlex, verify with the journal
Papers published in 2025
104
OpenAlex works

Check before you submit

  • Confirm the current article processing charge, waivers, and any institutional agreement on the journal website; the OpenAlex figure is indicative.
  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q1
Subfield Quartile
B3
CAS Block

Ranking and source check

#722
of 6,272 Medicine field journals
#721
among Q1 Medicine journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
3,097
H-Index
135
Fully Open Access
No
Recent OA Works
640
Subject Areas
Geriatrics and GerontologyFamily PracticePsychiatry and Mental healthEconomics and Econometrics

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to Drugs & Aging

  1. 1

    Check the scope

    OpenAlex classifies Drugs & Aging's papers in subfields including Geriatrics and Gerontology, Family Practice, and Psychiatry and Mental health. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    Drugs & Aging homepage ↗
  3. 3

    Submit online

    Use the submit link in Drugs & Aging's author guidelines; Adis, Springer Healthcare runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.

  4. 4

    Plan for costs

    OpenAlex lists an indicative article processing charge of $4,990 USD. Check the current fee, waivers, and any institutional agreement on the journal website.

  5. 5

    Know what to expect

    Drugs & Aging does not publish an acceptance rate.

New on PubMed

What's new in your field?

Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.

See a demo:GLP-1CRISPRLong COVID

Reviewer Two · coming soon

Know what reviewers will say before you submit to Drugs & Aging

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about Drugs & Aging

Is Drugs & Aging a good journal?

Yes. By citation data, Drugs & Aging is a strong journal: it is Q1 in Geriatrics and Gerontology and 3 other subfields and ranks #722 of 6,272 Medicine journals by Journal Metrics Score (top 12%). Drugs & Aging's 2026 Journal Metrics Score is 4.3. OpenAlex lists an indicative article processing charge of $4,990 USD. OpenAlex classifies its papers in subfields including Geriatrics and Gerontology, Family Practice, and Psychiatry and Mental health, so check that your topic fits its scope.

What is Drugs & Aging's Journal Metrics Score in 2026?

Drugs & Aging's 2026 Journal Metrics Score is 4.3, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of Drugs & Aging?

We have not found an official acceptance rate published by Drugs & Aging or its publisher, and Journal Metrics does not estimate one because submission counts are not public. To judge selectivity, compare Drugs & Aging's quartile and score with similar journals, or ask the editorial office.

What quartile is Drugs & Aging in?

Drugs & Aging's best quartile is Q1. By OpenAlex subfield: Q1 in Geriatrics and Gerontology; Q1 in Family Practice; Q1 in Psychiatry and Mental health; Q1 in Economics and Econometrics. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Drugs & Aging will not match this score exactly. Compare journals using one source at a time.

How much does it cost to publish in Drugs & Aging?

OpenAlex lists an indicative article processing charge of $4,990 USD for Drugs & Aging. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.

Which journals are alternatives to Drugs & Aging?

Comparable journals include International Journal of Clinical Pharmacy, Drugs-Real World Outcomes, Pharmacy Education, and Deutsche Medizinische Wochenschrift. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to Drugs & Aging?

Submit online through the link in Drugs & Aging's author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter.

Cite an article from this journal
Back to Search